Large B diffuse lymphoma, also known as diffuse large B-cell lymphoma, is considered cured when the disease is in sustained remission after treatment with periodic evaluations.
Diffuse large B-cell lymphoma needs to be reviewed every three to six months after the end of treatment, and each review needs to evaluate the efficacy of the treatment, if the evaluation of the efficacy of the disease is in a state of sustained remission for more than five years, it means that the patient has reached the standard of clinical cure.
The longer the period of sustained remission after treatment, the better, and the lower the recurrence rate. If the period of sustained remission after treatment is shorter, for example, recurrence within six months or one year, the prognosis is extremely poor, the effectiveness of re-treatment is low, and the overall survival period is shorter.
In order to maximize the improvement of the patient’s prognosis, patients with diffuse large B-cell lymphoma must be prognostically stratified, so that they can receive standardized treatment under the guidance of physicians according to the stratification, and the drugs include rituximab and cyclophosphamide.